UPDATE : Wednesday, June 26, 2019
상단여백
HOME Bio
294 shareholders file suit against Kolon TissueGene for damage compensation
  • By Jeong Sae-im
  • Published 2019.06.14 10:51
  • Updated 2019.06.14 10:51
  • comments 0

Kolon TissueGene said in a public filing on Thursday that its 294 minority shareholders were pursuing 9.28 billion won ($7.83 million) compensation for their investment losses through a lawsuit at the Seoul Central District Court.

The defendants include the company, CEO Noh Moon-jong, two former CEOs Lee Woo-sok and Lee Bum-sup, former Kolon Group Chairman Lee Woong-yeol, Kolon TissueGene CFO Kweon Soon-wook, and Kolon TissueGene’s outside director, Lee Jang-ik.

The compensation sought by the shareholders is 6.76 percent of the company’s equity capital.

“We will actively respond to the lawsuit by appointing a legal representative,” Kolon TissueGene said.

same@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Jeong Sae-im
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top